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The methanol extract from the stem bark of Terminalia superba (TSB), fractions (TSB1–7) and two compounds isolated following bio-assay
guided fractionation namely 3,4′-di-O-methylellagic acid 3′-O-β-D-xylopyranoside (1) and 4′-O-galloy-3,3′-di-O-methylellagic acid 4-O-β-D-
xylopyranoside (2) were evaluated for their antimycobacterial, antibacterial and antifungal activities. The broth microdilution, the microplate
Alamar Blue assay (MABA) and the agar disc diffusion methods were used for the investigations. The results of the antimycobacterial assays
showed that the crude extract, fractions TSB5–7 and compound 1 were able to prevent the growth of all the studied mycobacteria. The lowest
minimal inhibitory concentration (MIC) value of 39.06 µg/ml for this extract was recorded on both M. smegmatis and M. tuberculosis MTCS2.
The corresponding values were 19.53 µg/ml and 4.88 µg/ml for fractions and compounds respectively. The MIC determination results on other
organisms indicated values ranging from 19.53 to 78.12 µg/ml for TSB and compound 2 on 90.9% of the tested organisms, meanwhile compound
1 as well as fractions TSB 6 and 7 exhibited detectable MIC values on all studied microorganisms. The overall results provide promising baseline
information for the potential use of the crude extract from T. superba, fractions 6–7 and the tested compounds in the treatment of tuberculosis,
bacterial and fungal infections.
© 2009 SAAB. Published by Elsevier B.V. All rights reserved.Keywords: Antimicrobial activity; Combretaceae; Compounds; Fractions; Terminalia superba1. Introduction
The establishment of concrete scientific basis today is needed
to enable more rational exploitation of African medicinal plants.
Plant drugs are widely used in Africa for the treatment of many
ailments and constitute the first health recourse for about 80% of
the population (Sofowora, 1993). A number of pharmaceutical
products in current use are derived from plants (Cowan, 1999).
Medicinal plants are rich in compounds which may be potential
natural drugs and which may serve as alternative, cheap and
safe antimicrobials for the treatment of common ailments. The⁎ Corresponding author. Tel.: +237 75468927, +237 7355927, +237 5338455;
fax: +237 22226018.
E-mail address: kuetevictor@yahoo.fr (V. Kuete).
0254-6299/$ - see front matter © 2009 SAAB. Published by Elsevier B.V. All righ
doi:10.1016/j.sajb.2009.09.009present report is focused on Terminalia superba Engl. & Diels
(Combretaceae), a tree of about 30–50 m high. It is a member
of the genus Terminalia that comprises around 100 species
distributed in tropical regions of the world. T. superba is known
as “Akom” in Cameroon and is locally used in the treatment of
various ailments, including diabetes mellitus, gastroenteritis,
female infertility and abdominal pains (Adjanohoun et al.,
1996). The anti-diabetic activity of the stem bark of T. superba
on streptozotocin-induced diabetic rats was lately demonstrated
(Kamtchouing et al., 2006). Compounds 1 and 2 have previous-
ly showed β-glucosidase inhibitory activity (Tabopda et al.,
2008). Thus, the present work was, undertaken to evaluate the
antimycobacterial, antibacterial and antifungal activities of the
methanol extract from the stem bark of T. superba as well as the
fractions and compounds obtained following a bio-assay guided
fractionation.ts reserved.
Fig. 1. Chemical structures of compounds isolated from T. superba.
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2.1. Plant material
The stem bark of T. superba Engl. & Diels was collected from
Ebolowa, Southern region of Cameroon, in June 2004. The plant
was identified at the Cameroon National Herbarium, Yaounde,
(by Mr. Victor Nana) where a voucher specimen (W.C.S. 3642a/
12543/Ya) was deposited.
2.2. Extraction and bio-assay guided purification
The air-dried and powdered stem bark (free from endotoxin;
1.5 kg) of T. superba was extracted by maceration in methanol
(6 L) at room temperature for 48 h. The filtrate was then
concentrated under vacuum to give a dark crude extract (TSB)
(73 g). The extract (55 g) was subjected to a silica gel-60
column chromatography and eluted with hexane–ethyl acetate
(hex–EtOAc) and ethyl acetate–methanol (EtOAc–MeOH)
gradients. One hundred and forty five fractions of 150 ml
each were collected as follows: hex (1–12), hex–EtOAc 75:25
(13–38), hex–EtOAc 50:50 (39–55), hex–EtOAc 25:75 (56–
77), EtOAc (78–91), EtOAc–MeOH 95:5 (92–115), MeOH
(116–145). These fractions were then pooled following analytic
TLC in seven new fractions: TSB1 (1–8; 1.8 g), TSB1 (9–26;
2.1 g), TSB3 (27–42; 3.2 g), TSB4 (43–61; 3.6 g), TSB5 (62–
86; 5.4 g), TSB6 (87–106; 11.5 g), TSB7 (107–145; 15.8 g).
On the basis of the antimicrobial investigations of the above
fractions, TSB6 and TSB7 were each subjected to a second
column chromatography. Eight grams of TSB6 were passed
through Sep-Pak C18-cartridges (15 g) using H2O–MeOH and
CHCl3 as eluents to yield a grey powder identified as ellagic
acid (C14H6O8) (3; 16 mg, Mw: 302.20, mp 361–362 °C)
(Grzegorz and Jaromir, 1996) and a crystal from methanol
identified as 4′-O-galloy-3,3′-di-O-methylellagic acid 4-O–β–
D-xylopyranoside (C28H22O16) (2, 56 mg, Mw: 613.0824, mp
204–206 °C) (Tabopda et al., 2008). TSB7 (10 g) was purified
on Sephadex LH-20 (Pharmacia) CC with H2O/MeOH gradient
to yield compound 2 (13 mg) and crystals (from methanol)
identified as 3,4′-di-O-methylellagic acid 3′-O-β-D-xylopyr-
anoside (C21H18O12) (1, 93 mg, Mw: 461.0791, mp 194–
196 °C) (Tabopda et al., 2008). The chemical structures of the
isolated compounds are presented in Fig. 1.2.3. General procedure
IR spectra were recorded on an ATI Mattson Genesis Series
FTIR spectrometer as KBr disc. 1H-NMR, 13C-NMR, two-
dimensional COSY, ROESY, HSQC and HMBC analysis were
performed on a Bruker Avance DPX instrument (300 MHz and
500 MHz for 1H and 75 MHz for 13C). The 2.50 and 40.0 ppm
resonances of residual CD3SOCD3 were used as internal
references for 1H and 13C-NMR spectra, respectively. Mass
spectra were recorded on a micro TOF instrument. All melting
points were determined on a micro-melting point apparatus and
were uncorrected. The structures of the compounds wereconfirmed by comparing with reference data from available
literature.
2.4. Microbial strains
The tested organisms included: Mycobacteria namely; My-
cobacterium smegmatis ATCC 700084, drug-susceptible strain
of Mycobacterium tuberculosis H37Rv ATCC 27294 (America
Type Culture Collection, Rockville, MD, USA), two clinical
strains of M. tuberculosis MTCS1, M. tuberculosis MTCS2,
and a methicillin-resistant Staphylococcus aureus LMP805
(Gram-positive bacterium), six Gram-negative bacteria namely:
β-lactamase positive (βL+) Escherichia coli LMP701; βL+-
Shigella dysenteriae LMP606; Ampicillin-resistant Klebsiella
pneumoniae LMP803; Carbenicillin-resistant Pseudomonas
aeruginosa LMP804; Chloramphenicol-resistant Salmonella
typhi LMP706; Chloramphenicol-resistant Citrobacter freundii
LMP802 and four fungi namely: Candida albicans LMP709U;
Candida glabrata LMP0413U; Microsporum audouinii
LMP725D and Trichophyton rubrum LMP0723D. Each drug
to which a microorganism was resistant was used as specific
antibiotic (SA) in this study. The clinical isolates were obtained
from Yaoundé General Hospital (Cameroon) and their identity
was confirmed before use as previously reported (Mbaveng
et al., 2008).
2.5. Culture media
M. smegmatis was cultured on Middlebrook 7H11 agar
(7H11) and allowed to grow for 24 h. M. tuberculosis was
plated on Löwenstein–Jensen medium and allowed to grow for
3–4 weeks at 37 °C. The 7H9 broth was used to determine the
minimal inhibitory concentrations (MIC) and the minimal
microbicidal concentrations (MMC) of the test samples on
M. smegmatis and M. tuberculosis. Nutrient Agar (NA) was
used for other bacteria. Sabouraud Glucose Agar was used for
the activation of the fungi meanwhile the Mueller Hinton broth
(MHB) was used to determine the MIC of all samples against
the tested pathogens. The MHB and Mueller Hinton Agar
(MHA) was used to determine the MMC of the active samples.
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Ciprofloxacin and isoniazid (INH) (Sigma-Aldrich) were
used as positive controls for M. smegmatis and M. tuberculosis
respectively. Nystatin (Maneesh Pharmaceutic PVT. Ltd.,
Govandi, Mumbai, 400 043 India) and gentamicin {Jinling
Pharmaceutic (Group) corp., Zhejang Tieng Feng Pharmaceutic
Factory, No. 11 Chezhan Road, Huzhou City, Zhejang, China)
were used as reference antibiotics (RA) against fungi and
bacteria respectively.
2.7. Microplate susceptibility testing against Mycobacterium
smegmatis
All samples were tested against M. smegmatis using the
microplate dilution method. The MIC, MMC and bacteria
preparations were performed in 96-well microplates according
to Salie et al. (1996) and Newton et al. (2002). The crude extract
was dissolved in 10% dimethylsulfoxide (DMSO) in sterile 7H9
broth. Serial twofold dilutions of each sample to be evaluated
were made with 7H9 broth to yield volumes of 100 µl/well with
final concentrations ranging from 0.31 to 78.12 µg/ml for the
crude extract and fractions, 0.16–39.06 µg/ml for compounds 1
and 2. Ciprofloxacin served as the positive drug-control. One
hundred microlitres of M. smegmatis (106 CFU/ml) was also
added to each well containing the samples and mixed
thoroughly at the same concentration range as above. The
solvent control; DMSO at 2.5% or less in each well did not
show inhibitory effects on the growth of M. smegmatis. Tests
were done in triplicates and the cultured microplates were
sealed with parafilm and incubated at 37 °C for 24 h. The MIC
of each sample was detected following addition (40 µl) of
0.2 mg/ml p-iodonitrotetrazolium chloride (INT, Sigma-
Aldrich, South Africa) and incubated at 37 °C for 30 min
(Eloff, 1998; Mativandlela et al., 2006). Viable bacteria reduced
the yellow dye (INT) to pink. MIC was defined as the lowest
sample concentration that prevented this change and exhibited
complete inhibition of bacterial growth. The MMC was
determined by adding 50 µl aliquots of the preparations
(without INT), which did not show any growth after incubation
during MIC assays, to 150 µl of 7H9 broth. These preparations
were incubated at 37 °C for 48 h. The MMCwas regarded as the
lowest concentration of extract, which did not produce a color
change after addition of INT as mentioned above.
2.8. Antituberculosis activity: MABA susceptibility testing
The activity of all samples againstM. tuberculosiswas tested
using the microplate Alamar Blue assay (MABA) according to
Collins and Franzblau (1997), as modified by Jimenez-
Arellanes et al. (2003). Briefly, each of the above strains was
cultured at 37 °C in Middlebrook 7H9 broth (Becton Dickinson,
Sparks, MD) supplemented with 0.2% glycerol (Sigma
Chemical Co., St. Louis, MO) and 10% OADC (oleic acid–
albumin–dextrose–catalase; Becton Dickinson) until logarith-
mic growth was reached. Each culture was mixed with a
sufficient volume of sterile supplemented Middlebrook 7H9broth to achieve a turbidity equivalent to that ofMcFarland's N° 1
standard. To obtain the test inoculum, this suspension was further
diluted 1:50 v/v with the same culture medium to approximately
6×106 colony-forming units (CFU/ml) immediately before use.
The crude extract and compounds were dissolved in 100%
dimethylsulfoxide (DMSO, Sigma), then diluted in a fresh
supplemented Middlebrook 7H9 broth. These samples as well as
INH were diluted to their final concentrations ranging from 0.31
to 78.12 µg/ml for the crude extract and fractions, 0.16–39.06 µg/
ml for compounds 1 and 2. The final concentration of DMSO in
all assays was 2.5% or less, which is nontoxic for mycobacteria.
The samples were assayed twice in duplicate. All tests were
carried out in sterile flat-bottomed 96-well microplates. Sterile
double-distilled water (100 µl) was poured into the wells on the
outer perimeters of the microplates, and 100 µl of Middlebrook
7H9 broth supplemented with OADCwas added to the remaining
(test) wells. Each microplate was incubated for 5 days at 37 °C in
a 5% CO2 atmosphere (in a sealed plastic CO2-permeable bag).
After 5 days of incubation, 32 µl of a mixture of freshly prepared
Alamar Blue solution (Sigma) and 20% sterile Tween-80 (Sigma)
1:1 v/v) were added to one growth-control well. The microplates
were incubated again at 37 °C for 24 h. If a color shift from blue to
pink was observed in the growth-control sample, 32 µl of Alamar
Blue solution was then added to each of the remaining wells, and
themicroplate was further incubated for 24 h. Awell defined pink
color was interpreted as positive bacterial growth, whereas a blue
color indicated an absence of growth. The MIC corresponded to
the greatest dilution of sample extract inwhich the color shift from
blue to pink was not observed.
2.9. Determination of mycobactericidal effect (MMC)
Samples with detected MIC values following MABA (Collins
and Franzblau, 1997; Jimenez-Arellanes et al., 2003) were
assayed for their mycobactericidal effect as follows. Two six-well
rows of a microplate were prepared with fresh Middlebrook 7H9
culture medium. Two-fold dilution series of the studied samples
and inoculum were set up as previously described, but only one
six-well row was used to confirm the MIC value with Alamar
Blue. Immediately thereafter, 5 µl of the undeveloped mycobac-
terial suspensions was transferred from the former to a new
microplate that contained 195 µl of fresh culture medium per
well. Three wells were inoculated with 100 µl of fresh inoculum
as forMABA and three more wells were incubated with 200 µl of
culture medium only (as negative controls). The microplates were
incubated and developed with Alamar Blue as for MABA. The
minimal bactericidal concentration (MMC) corresponded to the
minimum sample concentration that did not cause a color shift in
cultures re-incubated in fresh medium.
2.10. Preparation of discs
Whatmann filter paper (N° 1) discs of 6 mm diameter were
impregnated with 10 µl of the crude extract solution at 10 mg/ml
(100 µg/disc), fractions and isolated compounds at 4 mg/ml
(40 µg/disc), prepared using DMSO. The discs were evaporated
at 37 °C for 24 h. The RA discs and SA were prepared as
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discs containing 40 µg and 100 µg of drug respectively. Two
discs were prepared for each sample.2.11. Diffusion test
The antimicrobial diffusion test was carried out as described by
Jorgensen et al. (1999) using a cell suspension of about 1.5
106 CFU/ml obtained from aMcFarland turbidity standard N° 0.5.
The suspensionwas standardized by adjusting the optical density to
0.1 at 600 nm (SHIMADZU UV-120-01 spectrophotometer)
(Kuete et al., 2007a,b). This was used to inoculate, by flooding,
the surface of MHA plates. Excess liquid was air-dried under a
sterile hood and the impregnated discs were applied at equidistant
points on top of the agar medium. A disc prepared with only the
corresponding volume ofDMSOwas used as negative control. The
plates were incubated at 30 °C for 48 h (M. audouinii and
T. rubrum) or 37 °C for 24 h (other organisms). Antimicrobial
activity was evaluated by measuring the diameter of the inhibition
zone (IZ) around the disc. The assay was repeated twice in
duplicate and results were recorded as mean±SD of the duplicated
experiment.2.12. MIC and MMC determinations
The MICs of the crude extract, fractions, compounds 1 and 2
and reference antibiotics (RA) (gentamicin for bacteria and
nystatin for fungi) were determined as follows; the test samplewas
initially dissolved in dimethylsulfoxide (DMSO). The solution
obtained was then added to MHB to give a final concentration of
78.12 µg/ml. This was serially diluted two fold to obtainTable 1
Antimicrobial activity a of the crude extracts, fractions, compounds isolated from T.
Tested organisms Tested samples b
Crude extract Fractions
TSB TSB1 TSB2 TSB3 TSB4
Bacteria
Staphylococcus aureus 19.0±1.0 11.5±0.0 11.0±0.0 10.0±0.0 12.5±1
Escherichia coli 15.0±0.0 8.0±0.0 8.0±0.0 10.0±0.0 12.0±1
Shigella dysenteriae 17.5±1.5 – – – 10.5±0
Klebsiella pneumoniae 16.0±0.0 – – – –
Pseudomonas aeruginosa 18.0±1.0 – – 8.0±0.0 10.0±0
Salmonella typhi 15.0±0.0 8.0±0.0 12.5±1.0 10.0±0.0 8.5±0.0
Citrobacter freundii 13.0±0.0 – – – –
Fungi
Candida albicans 17.5±0.0 – 11.0±0.0 10.5±0.5 11.0±1
Candida glabrata 14.0±0.0 – – – 8.0±0
Microsporum audouinii 19.5±0.5 – 12.0±0.0 12.5±0.0 8.0±0
Trichophyton rubrum 17.5±0.5 8.0±0.0 8.0±0.0 12.0±0.0 12.5±0
(–): Not active.
(nt): not tested.
a Antimicrobial activity: crude extract was tested at 100 µg/disc while fractions,
b The Tested samples were crude extract from the stem bark of T. superba
xylopyranoside 2: 4′-O-galloy-3,3′-di-O-methylellagic acid 4-O-β-D-xylopyranosid
SA: specific antibiotics (Methicillin for Staphylococcus aureus, amoxicillin fo
pneumoniae, Carbenicillin for Pseudomonas aeruginosa, Chloramphenicol for Salmconcentration ranges of 0.31 to 78.12 µg/ml. 100 µl of each
concentration was added in a well (96- wells microplate)
containing 95 µl of MHB and 5 µl of inoculum (standardized at
1.5 106 CFU/ml by adjusting the optical density to 0.1 at 600 nm
SHIMADZU UV-120-01 spectrophotometer) (Kuete et al.,
2007a,b). The final concentration of DMSO in the well was less
than 1% (preliminary analyses with 1% (v/v) DMSO do not affect
the growth of the test organisms). The negative control well
consisted of 195 µl of MHB and 5 µl of the standard inoculum
(Kuete et al., 2007a,b). The plateswere coveredwith a sterile plate
sealer, then agitated to mix the contents of the wells using a plate
shaker and incubated at 30 °C for 48 h (M. audouinii and
T. rubrum) or 37 °C for 24 h (other organisms). The assay was
repeated trice. The MIC of samples was detected following
addition (40 µl) of 0.2 mg/ml p-iodonitrotetrazolium chloride and
incubated at 37 °C for 30 min (Kuete et al., 2008). Viable bacteria
reduced the yellow dye to pink. MIC was defined as the lowest
sample concentration that prevented this change and exhibited
complete inhibition of bacterial growth.
For the determination of MMC, a portion of liquid (5 µl) from
eachwell that showed no change in color was plated onMHA and
incubated at 30 °C for 48 h (M. audouinii and T. rubrum or 37 °C
for 24 h (other organisms). The lowest concentration that yielded
no growth after this sub-culturing was taken as the MMC (Kuete
et al., 2007a,b).3. Results and discussions
The Bio-assay guided fractionation of TSB led to the isolation
of three main compounds, 3,4′-di-O-methylellagic acid 3′-O-β-D-
xylopyranoside (1), 4′-O-galloy-3,3′-di-O-methylellagic acid 4-O-superba and reference antibiotics determined by the disc diffusion test.
Compounds Antibiotics
TSB5 TSB6 TSB7 1 2 RA SA
.0 12.5±0.5 19.0±0.0 20.5±0.5 21.0±0.0 19.0±1.0 22.5±1.5 13.0±0.0
.0 10.5±0.5 14.5±0.5 14.5±0.5 13.0±0.0 13.0±0.5 24.0±2.0 12.5±1.0
.0 13.0±0.0 15.5±0.5 16.0±0.0 16.0±0.0 16.0±0.5 21.5±0.5 14.5±1.0
– 10.0±0.0 16.0±0.0 14.0±0.0 14.0±0.0 13.0±0.0 8.5±0.0
.0 8.0±0.0 17.5±0.5 18.0±0.0 17.5±0.5 12.0±0.0 20.5±1.5 10.0±0.0
– 16.0±0.0 16.0±0.0 18.5±0.5 16.5±0.5 18.0±0.0 14.5±0.5
8.0±0.0 12.5±0.5 14.0±1.0 12.0±0.0 9.0±0.0 21.5±1.0 11.0±0.0
.0 12.0±1.0 17.5±0.0 17.5±0.0 19.0±0.0 18.0±0.0 18.0±0.0 nt
.0 8.0±1.0 15.5±0.5 17.0±0.0 15.5±0.5 16.0±1.0 17.5±0.0 nt
.0 8.5±0.5 19.0±0.0 20.0±1.0 21.5±0.0 18.0±1.0 19.0±0.0 nt
.5 10.0±0.0 16.0±1.0 18.5±0.5 16.0±0.0 15.5±0.0 20.0±0.0 nt
compounds and RA at 40 µg/disc and SA at 100 µg/disc.
(TSB), fractions 1–7 (TSB1–7), 1: 3,4′-di-O-methylellagic acid 3′-O-β-D-
e, RA or Reference antibiotics (Gentamycin for bacteria, Nystatin for yeasts),
r Escherichia coli LMP701,Shigella dysenteriae, Ampicillin for Klebsiella
onella typhi and Citrobacter freundii.
Table 2
Minimum inhibition concentration (µg/ml) of the crude extracts, fractions, compounds isolated from T. superba and reference antibiotics.
Tested organisms a Tested samples b
Crude extract Fractions Compounds Antibiotics
TSB TSB1 TSB2 TSB3 TSB4 TSB5 TSB6 TSB7 1 2 RA SA
Mycobacteria
Mycobcaterium smegmatis 39.06 78.12 N78.12 N78.12 78.12 78.12 19.53 39.06 4.88 19.53 0.61 nt
Mycobcaterium tuberculosis H37Rv (ATCC 27294) 78.12 78.12 N78.12 N78.12 78.12 78.12 39.06 39.06 4.88 9.76 0.31 nt
Mycobcaterium tuberculosis MTCS1 78.12 N78.12 N78.12 N78.12 N78.12 78.12 39.06 39.06 19.53 39.06 N39.06 nt
Mycobcaterium tuberculosis MTCS2 39.06 78.12 N78.12 N78.12 N78.12 78.12 39.06 39.06 4.88 9.76 0.31 nt
Bacteria
Staphylococcus aureus 19.53 78.12 78.12 N78.12 78.12 78.12 19.53 19.53 9.76 39.06 9.76 39.06
Escherichia coli 78.12 N78.12 N78.12 N78.12 78.12 N78.12 39.06 39.06 39.06 39.06 4.88 N39.06
Shigella dysenteriae 39.06 – – – N78.12 78.12 19.53 19.53 19.53 19.53 9.76 39.06
Klebsiella pneumoniae 78.12 – – – – – 78.12 19.53 39.06 39.06 39.06 N39.06
Pseudomonas aeruginosa 19.53 – – N78.12 N78.12 N78.12 19.53 19.53 19.53 39.06 9.76 N39.06
Salmonella typhi 78.12 N78.12 78.12 N78.12 N78.12 – 19.53 19.53 19.53 19.53 19.53 39.06
Citrobacter freundii N78.12 – – – – 78.12 39.06 78.12 78.12 N78.12 9.76 N39.06
Fungi
Candida albicans 39.06 – 78.12 N78.12 N78.12 78.12 19.53 19.53 19.53 19.53 19.53 nt
Candida glabrata 78.12 – – – N78.12 N78.12 19.53 19.53 19.53 19.53 19.53 nt
Microsporum audouinii 19.53 – 78.12 78.12 N78.12 N78.12 19.53 19.53 9.76 19.53 19.53 nt
Trichophyton rubrum 39.06 N78.12 N78.12 78.12 78.12 N78.12 19.53 19.53 19.53 39.06 9.76 nt
(–): Not determined as the sample was not active following the diffusion test.
(nt): not tested.
a The tested microorganisms were S. aureus: Staphylococcus aureus, E. coli: Escherichia coli, S. dysenteriae: Shigella dysenteriae, K. pneumoniae: Klebsiella
pneumoniae, P. aeruginosa: Pseudomonas aeruginosa, S. typhi: Salmonella typhi, C. freundii: Citrobacter freundii, C. albicans: Candida albicans, C. glabrata:
Candida glabrata, M. audouinii: Microsporum audouinii, T. rubrum: Trichophyton rubrum.
b The Tested samples were crude extract from the stem bark of T. superba (TSB), fractions 1–7 (TSB1–7), 1: 3,4′-di-O-methylellagic acid 3′-O-β-D-
xylopyranoside 2: 4′-O-galloy-3,3′-di-O-methylellagic acid 4-O-β-D-xylopyranoside, RA or Reference antibiotics (Gentamycin for bacteria, Nystatin for yeasts,
isoniasid for M. tuberculosis); SA: specific antibiotics (Methicillin for Staphylococcus aureus, amoxicillin for Escherichia coli LMP701,Shigella dysenteriae,
Ampicillin for Klebsiella pneumoniae, Carbenicillin for Pseudomonas aeruginosa, Chloramphenicol for Salmonella typhi and Citrobacter freundii.
Table 3
Minimum microbicidal concentration (µg/ml) of the crude extracts, fractions, compounds isolated from T. superba and reference antibiotics.
Tested organisms a Tested samples b
Crude extract Fractions Compounds Antibiotics
TSB TSB1 TSB2 TSB3 TSB4 TSB5 TSB6 TSB7 1 2 RA SA
Mycobcaterium smegmatis 78.12 N78.12 nd nd N78.12 N78.12 39.06 78.12 9.76 N39.06 2.44 nt
Mycobcaterium tuberculosis H37Rv (ATCC 27294) N78.12 N78.12 nd nd N78.12 N78.12 78.12 78.12 9.76 19.53 0.61 nt
Mycobcaterium tuberculosis MTCS1 N78.12 nd nd nd nd N78.12 N78.12 78.12 39.06 N39.06 nd nt
Mycobcaterium tuberculosis MTCS2 78.12 N78.12 nd nd nd N78.12 78.12 78.12 9.76 39.06 0.61 nt
Bacteria
Staphylococcus aureus 39.06 N78.12 N78.12 nd N78.12 N78.12 N78.12 78.12 39.06 78.12 19.53 N39.06
Escherichia coli N78.12 nd nd nd N78.12 nd N78.12 78.12 78.12 78.12 9.76 nt
Shigella dysenteriae 78.12 – – – nd N78.12 39.06 39.06 39.06 39.06 19.53 78.12
Klebsiella pneumoniae N78.12 – – – – – N78.12 78.12 78.12 78.12 78.12 nt
Pseudomonas aeruginosa 78.12 – – nd nd nd 78.12 39.06 39.06 78.12 19.53 nt
Salmonella typhi N78.12 nd N78.12 nd nd – 39.06 39.06 39.06 39.06 39.06 N39.06
Citrobacter freundii nd – – – – N78.12 78.12 N78.12 N78.12 nd 19.53 nt
Fungi
Candida albicans N78.12 – N78.12 nd nd N78.12 39.06 39.06 39.06 39.06 39.06 nt
Candida glabrata N78.12 – – – nd nd N78.12 78.12 78.12 78.12 39.06 nt
Microsporum audouinii 39.06 – N78.12 N78.12 nd nd 39.06 39.06 19.53 39.06 39.06 nt
Trichophyton rubrum N78.12 nd nd N78.12 N78.12 nd 78.12 39.06 39.06 78.12 19.53 nt
(–): Not tested as the MIC was not determined; (nd): not determined because the MMCN78.12 µg/ml (nt): not tested.
a The tested microorganisms were S. aureus: Staphylococcus aureus, E. coli: Escherichia coli, S. dysenteriae: Shigella dysenteriae, K. pneumoniae: Klebsiella
pneumoniae, P. aeruginosa: Pseudomonas aeruginosa, S. typhi: Salmonella typhi, C. freundii: Citrobacter freundii, C. albicans: Candida albicans, C. glabrata:
Candida glabrata, M. audouinii: Microsporum audouinii, T. rubrum: Trichophyton rubrum.
b The Tested samples were crude extract from the stem bark of T. superba (TSB), fractions 1–7 (TSB1–7), 1: 3,4′-di-O-methylellagic acid 3′-O-β-D-
xylopyranoside 2: 4′-O-galloy-3,3′-di-O-methylellagic acid 4-O-β-D-xylopyranoside, RA or Reference antibiotics (Gentamycin for bacteria, Nystatin for yeasts,
isoniasid for M. tuberculosis), SA: specific antibiotics (Methicillin for Staphylococcus aureus, amoxicillin for Escherichia coli LMP701,Shigella dysenteriae,
Ampicillin for Klebsiella pneumoniae, Carbenicillin for Pseudomonas aeruginosa, Chloramphenicol for Salmonella typhi and Citrobacter freundii.
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(3) (Grzegorz and Jaromir, 1996). These compounds together with
3,3′-di-O-methylellagic acid, 3,3′-di-O-methyl ellagic acid 4-O-β-
D-xylopyranoside were previously isolated from T. superba
(Tabopda et al., 2008). In the present report, we have evaluated
the antimycobacterial, antibacterial and antifungal activities of
T. superba extract, fractions and compounds 1 and 2 obtained
following a bio-assay guided process. The results are recorded in
Tables 1–3.
The results of the antimycobacterial assays (Table 2), showed
that the crude extract, fractions TSB5–7 and compound 1were able
to prevent the growth of all the studied mycobacteria in the tested
concentration range. The lowest MIC value (39.06 µg/ml) for this
extract was recorded on both M. smegmatis and M. tuberculosis
MTCS2. The corresponding values were 19.53 µg/ml for fractions
(TSB6 on M. smegmatis) and 4.88 µg/ml for compounds
(compound 1 on three of the four studied mycobacterial species).
The MICs recorded with compound 1 (19.53 µg/ml) and 2
(39.06 µg/ml) onM. tuberculosisMTCS1were lower than those of
INH (N39.06 µg/ml). The obtained data highlighted the significant
antimycobacterial potency of the two compounds as well as that of
the crude extract, fractions TSB6 and TSB7. Results of the MMC
determination (Table 3) showed detectable values for fraction
TSB7 and compound 1.Akeen look of the results in Tables 2 and 3
shows that the recorded MMC values were not more than fourfold
their corresponding MICs. This suggests that bactericidal effect of
studied samples could be expected (Mims et al., 1993). The use of
M. smegmatis in this assay was a preliminary step to select the
concentration range to be tested on M. tuberculosis species. The
results as obtained validated the necessity of such experiments.
However, it is well known that the sensitivity of M. smegmatis is
closer to that of M. tuberculosis and that this non pathogenic
mycobacterial species can be used in selecting samples for
M. tuberculosis studies (Newton et al., 2002).
Tables 1–3 also summarize the results of the antimicrobial
assays against fungi, Gram-positive and negative bacteria. Results
of Table 1 demonstrated that the crude extract from T. superba
(TSB), fractions TSB6–7 as well as the two tested compounds
exhibited microbial growth inhibition on all the tested organisms
at the tested concentrations. The IZ obtained ranged from 13 to
19.5 mm for TSB, 10–19 mm and 14–20.5 mm respectively for
TSB6 and TSB7. Compounds 1 and 2 showed IZ ranging from 12
to 21.5 mm and 9 to 19 mm respectively. Other fractions were
selectively active. Their inhibition effects were noted on 9/11
(81.8%) tested microbial species for TSB4 and TSB5, 7/11
(74.3%) for TSB3, 6/11 (55.5%) for TSB2 and 4/11 (36.4%) for
TSB1. The highest IZ were obtained against M. audouinii for
TSB, and S. aureus for TSB8, compounds 1 and 2.
The results of MIC determinations (Table 2) indicate values
ranging from19.53 to 78.12 µg/ml for the TSBand compound 2on
90.9% (10/11) of the tested organisms. Within the tested interval
(0.31–78.12 µg/ml), compounds 1 aswell as fractions TSB6 and 7
showed evidentMIC values on the entire set of the testedmicrobial
strains. Against the 11 tested organisms, detectable MIC values
were recorded on 4 (36.4%) for TSB2 and TSB5, 3 (27.3%) for
TSB4, 2 (18.2%) for TSB3 and 1 (9.1%) for TSB1. The lowest
MICvalue for the crude extract (19.53 µg/ml)was recorded againstS. aureus, P. aeruginosa and M. audouinii. This lowest value was
also noted with fractions 6 and 7 on all tested fungi, and onmost of
the tested bacterial species. The corresponding value for the tested
compounds (9.76 µg/ml) was obtained with compound 1 against
S. aureus and M. audouinii. The reference antibiotics exhibited
MIC values ranging from 4.88 to 39.06 µg/ml. The inhibition
potentials of the crude extract, fractions 6 and 7 as well as that of
compounds 1 and 2 can be considered significantly importantwhen
regarding the antibacterial and antifungal activities of the RA. This
can be highlighted by the MIC value obtained for compound 1 on
M. audouinii (activity two fold greater than that of nystatin). Apart
from the activity exhibited by compound 2 (MIC: 39.06 µg/ml) on
T. rubrum, the preceding samples showed equal or greater
antifungal activity compared to nystatin on the four tested fungi.
The results of the MMC determinations (Table 3) indicated
noticeable values for TSB on 36.4% (4/11) of the tested organisms.
This assay also confirmed the interesting activity of fractions 6, 7,
compounds 1 and 2. Detectable MMC values were recorded
against 90.1% (10/11) of the tested organisms for fraction TSB7,
compounds 1 and 2 and against 63.6% (7/11) for fraction TSB6.
These data suggest that cidal effect of the tested samples could be
expected (Kuete et al., 2007a,b, 2008). Furthermore, the activities
of the crude extract, fractions 6 and 7 as well as those of the two
tested compounds (1 and 2) could be considered as very important
since the tested organisms were resistant to commonly used
antibiotics. Compounds 1 and 2 appeared to be the main active
principles when considering the microorganisms tested in the
present study.
The results from this study are in accordance with previous
biological reports on the genus Terminalia. The antimicrobial
activity has been demonstrated for a number of Terminalia species
such as T. catappa (Kloucek et al., 2005), T. sericea (Steenkamp
et al., 2007), T. glaucescens (Magassouba et al., 2007) etc.
T. chebula ripe seeds extract was found to be active against Sta-
phylococcus aureus (Bonjar, 2004). Eldeen et al. (2006)
demonstrated the antibacterial activity (against both Gram-positive
and Gram-negative bacteria) of anolignan B isolated from
T. sericea. Some of the bioactive compounds from Terminalia
species include 23-galloylarjunolic acid and its β-glucopyranosyl
ester, terminolic acid, arjunic acid, arjungenin, arjunglucoside,
sericic acid and sericoside isolated from T. macroptera (Conrad
et al., 1998). The present study also identified compounds 1 and 2
as other active principles of the genus Terminalia. Antimicrobial
pentacyclic triterpenoids from the stem bark were also identified
from this plant (Tabopda et al., 2009). Also, compounds 3 (ellagic
acid) was reported for its antimicrobial activities on S. aureus,
S. epidermidis,Micrococcus luteus, E. coli, B. subtilis, C. albicans
(Cowan, 1999; Akiyama et al., 2001; Thiem and Goslinska, 2004).
However, this compound was isolated in a limited amount in
T. superba and could not be tested in this study. Ellagic acid-like
compounds have been found to complex proteins (Scalbert, 1991;
Haslam, 1996; Stern et al., 1996), inactivatingmicrobial adhesions,
enzymes, cell envelope transport proteins, etc.
The overall results provide promising baseline information for
the potential use of the crude extracts from the stem bark of
T. superba, fractions 6 and 7 as well as the two tested isolated
compounds in the treatment of tuberculosis, and other bacterial and
131V. Kuete et al. / South African Journal of Botany 76 (2010) 125–131fungal infections. However, this will further be confirmed by
pharmacological and toxicological studies currently going on in
our laboratory.
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